Drug intelligence / Profile preview

ADM03820

Development stage: Discontinued
Lead developer: Ology Bioservices
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular, Intravenous

Overview

**ADM03820** is an investigational, fixed 1:1 cocktail of two engineered human anti-SARS-CoV-2 monoclonal antibodies, COV2-2130-YTE-LALA and COV2-2381-YTE-LALA. The antibodies bind non-overlapping epitopes within the receptor-binding domain of the SARS-CoV-2 spike glycoprotein and neutralize viral entry. YTE Fc substitutions were introduced to extend antibody persistence, while LALA substitutions reduce Fc gamma receptor-mediated effector functions. The program was originated from antibodies discovered at Vanderbilt University Medical Center and advanced for intramuscular COVID-19 pre-exposure prophylaxis by Resilience Government Services. A Phase 1 study was completed, while a planned Phase 2/3 prevention study was withdrawn.

Other names: ADM-03820ADM03820ADM 03820

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on ADM03820.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADM03820.

Explore the full profile